Want to see JP:4582 full AI Analyst Report?
4582 Stock Chart & Stats
¥68.00
¥1.00(1.52%)
At close: 4:00 PM EDT
¥68.00
¥1.00(1.52%)
Day’s Range― - ―
52-Week Range¥65.00 - ¥229.00
Previous CloseN/A
Volume398.00K
Average Volume (3M)577.10K
Market Cap
¥5.19B
Enterprise Value¥6.62K
Total Cash (Recent Filing)¥1.90B
Total Debt (Recent Filing)¥1.03B
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-106.26
Shares Outstanding76,434,210
10 Day Avg. Volume434,010
30 Day Avg. Volume577,100
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialty, Partnership-driven ModelSymbio's business model mixes direct commercialization with collaboration and licensing revenue, which spreads development risk and creates multiple durable revenue channels. Partnerships can fund late-stage programs, extend geography, and provide non-dilutive milestone/royalty cash over time.
Proven Prior ProfitabilityThe company produced solid profits in 2021–2022, demonstrating product-market fit and operational capability. That track record indicates existing commercial infrastructure and potential to return to profitability if revenue stabilizes or cost structure is tightened, a durable recovery lever.
High Gross Margins And Asset BaseRelatively high gross margins and a meaningful asset base support scalable manufacturing economics and provide collateral for financing or partnerships. These structural advantages help preserve recovery optionality and make future deals or credit access more feasible over months.
Bears Say
Sharp Revenue DeclineSustained steep revenue declines materially reduce operating leverage and shrink available resources for R&D, commercialization, and regulatory work. Over a multi-month horizon, lower top-line scale weakens bargaining power with partners and distributors, making margin recovery and growth harder to achieve.
Meaningful Cash BurnPersistent negative operating and free cash flow forces reliance on external financing or partnership funding. That elevates dilution or refinancing risk, constrains funding for trials and launches, and shortens the runway for strategic initiatives absent durable cash inflows or new capital.
Rising Leverage And Compressed EquityDebt emergence from zero to material levels while equity has eroded increases financial rigidity. Higher leverage raises interest and covenant pressure, limits strategic flexibility, and increases risk if losses persist, making the firm more vulnerable to funding stress over the coming months.
Symbio Pharmaceuticals Limited News
4582 FAQ
What was Symbio Pharmaceuticals Limited’s price range in the past 12 months?
Symbio Pharmaceuticals Limited lowest stock price was ¥65.00 and its highest was ¥229.00 in the past 12 months.
What is Symbio Pharmaceuticals Limited’s market cap?
Symbio Pharmaceuticals Limited’s market cap is ¥5.19B.
When is Symbio Pharmaceuticals Limited’s upcoming earnings report date?
Symbio Pharmaceuticals Limited’s upcoming earnings report date is Jul 30, 2026 which is yesterday.
How were Symbio Pharmaceuticals Limited’s earnings last quarter?
Symbio Pharmaceuticals Limited released its earnings results on May 07, 2026. The company reported -¥35.89 earnings per share for the quarter, missing the consensus estimate of N/A by -¥35.89.
Is Symbio Pharmaceuticals Limited overvalued?
According to Wall Street analysts Symbio Pharmaceuticals Limited’s price is currently Overvalued.
Does Symbio Pharmaceuticals Limited pay dividends?
Symbio Pharmaceuticals Limited does not currently pay dividends.
What is Symbio Pharmaceuticals Limited’s EPS estimate?
Symbio Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Symbio Pharmaceuticals Limited have?
Symbio Pharmaceuticals Limited has 76,434,210 shares outstanding.
What happened to Symbio Pharmaceuticals Limited’s price movement after its last earnings report?
Symbio Pharmaceuticals Limited reported an EPS of -¥35.89 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Symbio Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in JP:4582
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
Technical Analysis
Solasia Pharma KK
―
Wakamoto Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Medrx Co., Ltd.
―